What is frailty? How does it affect RA outcomes? Pop based cohort study 13000+ RA vs. 26000+ matched ctrl Over 2x more frailty 5.6% vs 2.6% OR frailty in RA 2.3 Adjusted for rurality, neighborhood income quartiles AND BL comorbidities index @RheumNow #ACR23 ABST1275 https://t.co/ZkOpgHPSE0

17% of 1st degree relatives AS pts had MRI- defined sacroiliitis, however not all of them were diagnosed w/ SpA due to absence of back pain. 25% w/ 1st degree AS relative met the classification criteria for SpA #ACR23 Abs #1403 https://t.co/W1T9ZqD4o1 @rheumnow https://t.co/DnaNSLiqfU

SMART study #ACR23 Plenary abs #1583: po split-dose MTX (vs single dose) once weekly in RA pts had ^^ efficacy & reduced need for add'l DMARDs. No major AE, but slight increase in frequency of persistent transaminitis in split-dose group. https://t.co/wHzjpSnfuA @rheumnow https://t.co/0hNTMGbt47

Large VA study of >1k RA-ILD pts No difference in risk of respiratory hospitalization or death in RA-ILD pts using TNFi vs. nonTNFi/JAKi Data does not support avoiding TNFi in RA-ILD @RheumNow #ACR23 Abs#1582 https://t.co/LTNLXEIAPo

Ab#1582 @RheumNow #ACR23 RA-ILD outcomes of TNFi v non-TNF b/tsDMARD VA Data, propens match emulation study No incr risk of death in TNFi vs non-TNFi But are TNF safe? - Don't support systematic avoidance. But are there specific pops - unsure. Don't answer if efficacy in RA-ILD https://t.co/AApEjZs4DM

Important plenary session, RA-ILD outcomes in VA cohort study No difference in death/hospitalization for TNF vs non-TNF treated patients. Jives w/my priors; I do NOT avoid TNF in RA-ILD Encouraging if you (like me) prefer RA-active tx for RA-ILD 😉😆 @RheumNow #ACR23 #ACRBest https://t.co/TIDzMLOfs4

World's largest jSSc cohort: djSSc pts had more severe dz vs ljSSc pts. DjSSc pts w/ more cutaneous, vascular, MSK involvement vs ljSSc pts w/ more cardiac involvement. No significant differences in ILD, PAH, GI involvement. #ACR23 Abs #1623 https://t.co/czAH0hpY2a @rheumnow https://t.co/RcfAJORXY3

Non TNFi b/tsDMARDs vs TNFi in RA-ILD. New-User, Propensity Score Matched Study. 454 patients. No difference! resp-related hospitalisation aHR 1.22 [0.92, 1.60] No difference mortality. Abstr#1582 #ACR23 #ACRbest @RheumNow https://t.co/HzzVo9dJHi https://t.co/mZuHq4GShU

The SMART study by Dhir et al: once-weekly, oral split-dose MTX (10mg/15mg) in RA pts had⬆️efficacy & ⬇️need for addtl DMARDs vs. once-weekly, single-dose MTX Reassuring. . . . In my practice, pts tolerate MTX split dosing better esp w/⬆️doses #ACR23 ABST1583 @RheumNow https://t.co/F8p2aKmmH4

#ACR23 Abs #1032 identified six major themes of diverse patient experiences. Studying patient experiences is critical for understanding mechanisms of health disparity, targeting interventions and, ultimately, improving quality of care. https://t.co/Fd2m4yzlHp @rheumnow https://t.co/EhIIF9cquQ

RheumNow’s expanded coverage of #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Long term follow up T2T in RA 12 yrs BeST & 20yrs IMPROVED studies 50% recalled 68% remission 91% LDA HAQ 0.5 These are GOOD outcomes Especially considering setup before we had several MoAs What’s lacking: current ttmt & number of bioD, ctrl group @RheumNow ABST1273 #ACR23 https://t.co/9KcsHLupJc

#ACR23 Abstr#1579 More data on the role of SGLT2-i in #SLE. Data from EHR using propensity match scoring showed the use of SGLT2-i vs DPP4-i (for nonSLE indication) was associated with reduced risk of MACE (HR:0.69)and poor renal outcomes inc. ESRD (HR:0.71) @RheumNow https://t.co/7k0o3m18AN